- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Impact of Recent Approvals and Novel Mechanisms
Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.
EP: 1.Understanding EGFR Mutations and First-Line Treatment
EP: 2.Overcoming Resistance Mechanisms and Addressing Unmet Needs
EP: 3.Impact of Recent Approvals and Novel Mechanisms
EP: 4.CNS Penetration and Efficacy of Emerging Therapies
EP: 5.Managing Adverse Events and Integrating Amivantamab Plus Lazertinib
EP: 6.Sequencing Therapies and Using the Most Effective Options First
EP: 7.The Value of Subcutaneous Therapy for Patients
EP: 8.FDA Approvals, Patient Selection, and SC Amivantamab
EP: 9.Counseling Patients on IV vs SC Administration
EP: 10.Improving Adherence and Transitioning to SC Therapy
EP: 11.Impact of SC Formulations on Pharmacy Operations
EP: 12.Barriers to Adoption of SC Therapies
Panelists discuss how recent regulatory approvals and innovative therapeutic mechanisms are expanding options for EGFR-positive non–small cell lung cancer (NSCLC). They explore the benefits of dual-targeting agents such as amivantamab, which simultaneously inhibits EGFR and MET, and next-generation tyrosine kinase inhibitors (TKIs) such as sunvozertinib that address resistance mutations. The discussion incorporates findings from recent studies, including FLAURA2, which demonstrated improved survival with osimertinib plus chemotherapy, balanced against higher toxicity. Panelists note how these new treatments and subcutaneous formulations are driving a shift toward more durable, mechanism-based, and patient-centered care strategies.
